Furthermore, the animal models allow to confirm that, particularly IGF1, directly inactivates HSCs, limits fibrosis in a p53-dependent manner and may be applied to treat NASH. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatohepatitis.